53. Pessanha de Carvalho L, Niepoth E, Mavraj-Husejni A, Kreidenweiss A, Herrmann J, Müller R, Knaab T, Burckhardt BB, Kurz T, Held J. Quantification of Plasmodium falciparum HRP-2 as an alternative method to [3H]hypoxanthine incorporation to measure the parasite reduction ratio in vitro. International Journal of Antimicrobial Agents. 2023 62 (3) 106894.

52. Berger A, Knak T, Kiffe-Delf AL, Mudrovcic K, Singh V, Njoroge M, Burckhardt BB, Gopalswamy M, Lungerich B, Ackermann L, Gohlke H, Chibale K, Kalscheuer R, Kurz T. Total Synthesis of the Antimycobacterial Natural Product Chlorflavonin and Analogs via a Late-Stage Ruthenium(II)-Catalyzed ortho-C(sp2 )-H-Hydroxylation. Pharmaceuticals 2022, 15, 984.

51. Martens CP, Van Mol P, Wauters J, Wauters E, Gangnus T, Noppen B, Callewaert H, Feyen JHM, Liesenborgs L, Heylen E, Velasquez C, Guler I, Engelen MM, Ockerman A, Vos R, Vandenbriele C, Meersseman P, Hermans G, Wilmer A, Martinod K, Burckhardt BB, Vanhove M, Verhamme P, Neyts J, Vanassche T. Dysregulation of the kallikrein-kinin pathway contributes to thromboinflammation in lungs of patients with COVID-19. eBioMedicine 2022;83:104195

50. Läer S, Cawello W, Burckhardt BB, Ablonczy L, Bajcetic M, Breur JMPJ, Dalinghaus M, Male C, de Wildt SN, Breitkreutz J, Faisal M, Keatley-Clarke A, Klingmann I, Lagler FB. Enalapril and enalaprilat pharmacokinetics in children with heart failure due to dilated cardiomyopathy and congestive heart failure after administration of an orodispersible enalapril minitablet (LENA-studies).  Pharmaceutics 2022, 14, 1163.

49. Gangnus T, Bartel A, Burckhardt BB. Mass spectrometric study of variation in kinin peptide profiles in nasal fluids and plasma of adult healthy individuals. J Transl Med. 2022 Mar 29;20(1):146. doi: 10.1186/s12967-022-03332-8.

48. Chamberlain R, Windolf H, Burckhardt BB, Breitkreutz J, Fischer B. Embedding a Sensitive Liquid-Core Waveguide UV Detector into an HPLC-UV System for Simultaneous Quantification of Differently Dosed Active Ingredients during Drug Release. Pharmaceutics. 2022 Mar 14;14(3):639. doi: 10.3390/pharmaceutics14030639

47. Marceau F, Rivard GE, Hébert J, Gauthier J, Bachelard H, Gangnus T, Burckhardt BB. Picomolar sensitivity analysis of multiple bradykinin-related peptides in the blood plasma of patients with hereditary angioedema in remission: a pilot study. Front. Allergy 2022.

46. Gangnus T, Burckhardt BB. Reliable Measurement of Plasma Kinin Peptides: Importance of Preanalytical Variables. Res Pract Thromb Haemost. 2022 Jan 12;6(1):e12646. doi: 10.1002/rth2.12646. eCollection 2022 Jan.

45. Majid H, Bartel A, Burckhardt BB. Predictivity of Standardized and Controlled Permeation Studies: Ex vivo – In vitro – In vivo Correlation for Sublingual Absorption of Propranolol. Eur J Pharm Biopharm 2021 Dec;169:12-19. doi: 10.1016/j.ejpb.2021.09.002. Epub 2021 Sep 9.

44. Majid H, Puzik A, Maier T, Merk R, Bartel A, Müller HC, Burckhardt BB. Formulation development of sublingual cyclobenzaprine tablets empowered by standardized and physiologically relevant ex vivo permeation studies. Pharmaceutics  2021 Sep 6;13(9):1409. doi: 10.3390/pharmaceutics13091409

43. Gangnus T, Burckhardt BB. Stabilization of short-lived peptides of the kallikrein-kinin system in human plasma to facilitate use as promising biomarkers. Clin Chem. 2021 Jul 29;hvab129. doi: 10.1093/clinchem/hvab129

42. Farahani S, Farahani I, Deters MA, Schwender H, Burckhardt BB, Läer S. Blended Learning on Blood Pressure Measurement: Investigating Two In-Class Strategies in a Flipped Classroom-Like Setting to Teach Pharmacy Students Blood Pressure Measurement Skills. Healthcare 2021 Jun 28;9(7):822. doi: 10.3390/healthcare9070822

41. Kottke D, Burckhardt BB, Knaab TC, Breitkreutz J, Fischer B. Development and Evaluation of a Composite Dosage Form Containing Desmopressin Acetate for Buccal Administration. Int J Pharm X. 2021

40. Majid H, Puzik A, Maier T, Eberhard D, Bartel A, Müller HC, Burckhardt BB. Exploring the Oromucosal Permeability of Cyclobenzaprine: A Comparative Preformulation by Standardized and Controlled Ex vivo and In Vitro Permeation Studies. Int J Pharm. 2021 Apr 5;601:120574. doi: 10.1016/j.ijpharm.2021.120574

39. Farahani S, Farahani I, Burckhardt BB, Monser K, Läer S. The development of an educational video on blood pressure measurement for pharmacy students. Adv Med Educ Pract. 2021; 12: 655–663. doi: 10.2147/AMEP.S302728

38. Gangnus T, Burckhardt BB. Targeted LC-MS/MS platform for the comprehensive determination of peptides in the kinin-kallikrein system. Anal Bioanal Chem. 2021 May;413(11):2971-2984. doi: 10.1007/s00216-021-03231-9

37. Knaab TC, Held J, Burckhardt BB, Rubiano K, Okombo J, Yeo T, Mok S, Uhlemann A, Lungerich B, Fischli C, Pessanha de Carvalho L, Mordmüller B, Wittlin S, Fidock DA, Kurz T. Development of orally active 3-hydroxy-propanamidines targeting Plasmodium falciparum malaria. J Med Chem. 2021 Mar 25;64(6):3035-3047. doi: 10.1021/acs.jmedchem.0c01744

36. Kottke D, Burckhardt BB, Breitkreutz J, Fischer B. Application and validation of a coaxial liquid core waveguide fluorescence detector for the permeation analysis of desmopressin acetate. Talanta. 2021 May 1;226:122145. doi: 10.1016/j.talanta.2021.122145

35. Gangnus T, Burckhardt BB. Sensitive mass spectrometric determination of kinin-kallikrein-system peptides in light of COVID-19. Sci Rep. 2021 Feb 4;11(1):3061. doi: 10.1038/s41598-021-82191-7

34. Burckhardt BB, Ciplea AM, Laven A, Klingmann I, Läer S, Kleine K, Dalinghaus M, Breur JMPJ, van der Meulen M, Swoboda V, Schwender H, Lagler FB. Simulation training to improve informed consent and PK/PD sampling in pediatric trials. Front Pharmacol. 2020 Dec 11;11:603042. doi: 10.3389/fphar.2020.603042

33. Feickert M, Burckhardt BB. Mass spectrometric studies on the peptide integrity of substance P and related human tachykinins in human biofluids. Peptides. 2021 Feb;136:170458. doi: 10.1016/j.peptides.2020.170458

32. Farahani S, Farahani I, Burckhardt BB, Schwender H, Laeer S. Self-Instruction Video Versus Face-to-Face Instruction of Pharmacy Students’ Skills in Blood Pressure Measurement. Pharmacy (Basel). 2020 Nov 16;8(4):217. doi: 10.3390/pharmacy8040217

31. Majid H, Bartel A, Burckhardt BB. Development, Validation and Standardization of Oromucosal Ex-vivo Permeation Studies for Implementation in Quality-controlled Environments. J Pharm Biomed Anal. 2021 Feb 5;194:113769. doi: 10.1016/j.jpba.2020.113769

30. Gangnus T, Burckhardt BB on behalf of the CARS consortium. Low-volume LC-MS/MS method for the pharmacokinetic investigation of carvedilol, enalapril and their metabolites in whole blood and plasma: application to a paediatric clinical trial. Drug Test Anal. 2021 Mar;13(3):694-708. doi: 10.1002/dta.2949

29. Burdman I, Burckhardt BB. Human prorenin determination by hybrid immunocapture LC-MS. A miscellaneous solvents triggered digestion using a D-optimal approach. Rapid Commun Mass Spectrom. 2020 Dec 30;34(24):e8932. doi: 10.1002/rcm.8932

28. Feickert M, Burckhardt BB. Validated Mass Spectrometric Assay for the Quantification of Substance P and human Hemokinin-1 in Plasma Samples: A Design of Experiments concept for comprehensive Method Development. J Pharm Biomed Anal. 2020 Nov 30;191:113542. doi: 10.1016/j.jpba.2020.113542

27. Burdman I, Burckhardt BB. Prorenin and active renin values in pediatrics: A bioanalytical review. Clin Chem Lab Med. 2020 Aug 19;59(2):275-285. doi: 10.1515/cclm-2020-0857

26. Gangnus T, Burckhardt BB. Improving sensitivity for the targeted LC-MS/MS analysis of the peptide bradykinin using a design of experiments approach. Talanta. 2020 Oct 1;218:121134. doi: 10.1016/j.talanta.2020.121134

25. Kottke D; Majid H; Breitkreutz J; Burckhardt BB. Development and Evaluation of a clinical appropriate buccal dosage form of lidocaine by ex vivo permeation studies. Int J Pharm. 2020 May 15;581:119293. doi: 10.1016/j.ijpharm.2020.119293

24. Makowski N; Ciplea AM; Ali M; Burdman I; Bartel A; Burckhardt BB on behalf of the LENA consortium. A comprehensive quality control system suitable for academic research - Application in a paediatric clinical study. Bioanalysis. 2020 Mar;12(5):319-333. doi: 10.4155/bio-2019-0242

23. Feickert M; Makowski N; Burdman I; Bartel A; Burckhardt BB on behalf of the LENA consortium. A continued method performance monitoring approach for the determination of pediatric renin samples - Application within a European pediatric clinical study. Clin Chem Lab Med. 2020 Oct 25;58(11):1847-1855. doi: 10.1515/cclm-2019-1162

22. Suessenbach FK; Makowski N; Feickert M; Gangnus T; Tins J; Burckhardt BB on behalf of the LENA consortium. A quality control system for ligand-binding assay of plasma renin activity: Proof-of-concept within a pharmacodynamic study. J Pharm Biomed Anal. 2020 Mar 20;181:113090. doi: 10.1016/j.jpba.2019.113090

21. Feickert M; Burckhardt BB. Design of experiments as concept for the minimization of nonspecific adsorption in the mass spectrometric determination of Substance P and related Hemokinin-1. J Sep Sci. 2020 Feb;43(4):818-828. doi: 10.1002/jssc.201901038

20. Burdman I; Burckhardt BB. A concept to make low-abundance endogenous renin accessible to mass spectrometry: A multistep experimental design approach. J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Dec 15;1134-1135:121856. doi: 10.1016/j.jchromb.2019.121856

19. Suessenbach FK; Tins J; Feickert M; Burckhardt BB on behalf of the LENA consortium. Customisation and validation of a low-volume plasma renin activity immunoassay: Enabling of regulatory compliant determination in paediatric trials. Pract Lab Med. 2019 Nov 12;17:e00144. doi: 10.1016/j.plabm.2019.e00144

18. Ali M; Tins J; Burckhardt BB on behalf of the LENA consortium. Fit-for-purpose quality assessment system for ensuring integrity of continued bioanalytical data within academia driven paediatric pivotal studies. AAPS J. 2020 Jan 29;22(2):37. doi: 10.1208/s12248-020-0415-x

17. Van Hecken A; Burckhardt BB; Khalil F; de Hoon J; Klingmann I; Herbots M; Laeer L; Lagler FB; Breitkreutz J. Relative Bioavailability of Enalapril Administered as Orodispersible Minitablets in Healthy Adults. Clin Pharmacol Drug Dev. 2020 Feb;9(2):203-213. doi: 10.1002/cpdd.728

16. Faisal M; Cawello W; Burckhardt BB; de Hoon J; Läer S. Simultaneous Semi-Mechanistic Population Pharmacokinetic Modeling Analysis of Enalapril and Enalaprilat Serum and Urine Concentrations From Child Appropriate Orodispersible Minitablets. Front Pediatr. 2019 Jul 9;7:281. doi: 10.3389/fped.2019.00281

15. Bajcetic M, De Wildt SN, Dalinghaus M, Breitkreutz J, Klingmann I, Lagler F, Keatley-Clarke A, Breur JMPJ, Male C, Jovanovic I, Szatmári A(†), Ablonczy L, Burckhardt BB, Cawello W, Kleine K, Obarcanin E, Spatenkova L, Swoboda V, van der Meulen M, Wagner P, Walsh J, Läer S. Orodispersible minitablets of enalapril for use in children with heart failure (LENA): rationale and protocol for a multicentre pharmacokinetic bridging study and follow-up safety study. Contemp Clin Trials Commun. 2019 Jun 8;15:100393. doi: 10.1016/j.conctc.2019.100393

14. Feickert M; Burckhardt BB. Substance P in cardiovascular diseases–A bioanalytical review. Clin Chim Acta. 2019 Aug;495:501-506. doi: 10.1016/j.cca.2019.05.014

13. Suessenbach FK; Burckhardt BB. Levels of angiotensin peptides in healthy and cardiovascular/renal diseased paediatric population - an investigative review. Heart Fail Rev. 2019 Sep;24(5):709-723. doi: 10.1007/s10741-019-09797-y

12. Makowski N; Burckhardt BB. Enabling insights into the maturation of the renin-angiotensin-aldosterone-system in children - Development of a low-volume LC-MS assay for the simultaneous determination of aldosterone, its precursor and main metabolite. Steroids. 2019 Aug;148:73-81. doi: 10.1016/j.steroids.2019.04.009

11. Gangnus T; Burckhardt BB. Potential and Limitations of Atrial Natriuretic Peptide as Biomarker in Pediatric Heart Failure – A Comparative Review. Front Pediatr. 2019 Jan 29;6:420. doi: 10.3389/fped.2018.00420

10. Faisal M; Cawello W; Burckhardt BB; Läer S. Model-dependent pharmacokinetic analysis of enalapril administered to healthy adult volunteers using orodispersible mini-tablets for use in pediatrics. Drug Des Devel Ther. 2019 Jan 25;13:481-490. doi: 10.2147/DDDT.S188417

9. Ali M; Läer S; Burckhardt BB. LC-MS/MS method for screening of intoxication and adherence of angiotensin converting enzyme inhibitors in plasma. Bioanalysis. 2018 Nov 6. doi: 10.4155/bio-2018-0200

8. Ciplea AM; Läer S; Burckhardt BB. A feasibility study in healthy adults to assess pharmacokinetic/pharmacodynamic sampling and sample preparation procedures, logistics and bioanalysis prior to an international multicentre paediatric study. Contemp Clin Trials Commun. 2018 Aug 21;12:32-39. doi: 10.1016/j.conctc.2018.08.008

7. Schaefer J; Burckhardt BB; Tins J; Bartel A; Läer S. Validated low-volume immunoassay for the reliable determination of direct renin especially valuable for pediatric investigations. J Immunoassay Immunochem. 2017;38(6):579-594. doi: 10.1080/15321819.2017.1350707

6. Schaefer J; Burckhardt BB; Tins J; Bartel A; Läer S. Validated low-volume aldosterone immunoassay tailored to GCLP-compliant investigations in small sample volumes. Pract Lab Med. 2017 Jul 27;9:28-38. doi: 10.1016/j.plabm.2017.07.004

5. Burckhardt BB, Läer S. Sample preparation and extraction in low-volume samples suitable for paediatric clinical studies – challenges, advances and experiences from a bioanalytical HPLC-MS/MS method validation using enalapril, enalaprilat and benazepril. Int J Anal Chem. 2015;2015:796249. doi: 10.1155/2015/796249

4. Burckhardt BB, Tins J, Ramusovic S, Läer S. Tailored assays for pharmacokinetic and pharmacodynamics investigations of aliskiren and enalapril in children: An application in serum, urine and saliva. J Pediatr Pharmacol Ther. Nov-Dec 2015;20(6):431-52. doi: 10.5863/1551-6776-20.6.431

3. Burckhardt BB, Tins J, Läer S. Bioanalytical liquid chromatography-tandem mass spectrometry method for determination of aliskiren in saliva and its application to a clinical trial with healthy volunteers. J Pharm Biomed Anal. 2014 Aug 5;96:118-26. doi: 10.1016/j.jpba.2014.03.021

2. Burckhardt BB, Tins J, Läer S. Simultaneous quantitative and qualitative analysis of aliskiren, enalapril and its active metabolite enalaprilat in undiluted human urine utilizing LC-ESI-MS/MS. Biomed Chromatogr. 2014 Dec;28(12):1679-91. doi: 10.1002/bmc.3201

1. Burckhardt BB, Ramusovic S, Tins J, Läer S. Determination of aliskiren in human serum quantities by HPLC- tandem mass spectroscopy appropriate for paediatric trials. Biomed Chromatogr. 2013 Apr;27(4):477-86. doi: 10.1002/bmc.2815